"Gilead has some big commercial challenges looming, and it’s tapped the leader who will spearhead them. The big biotech appointed longtime Amgen veteran Laura Hamill to its top commercial post, it said Tuesday. The move comes after an “extensive search” that began when James Meyers announced in February that he would retire. To take the Gilead post, Hamill will leave behind her position as Amgen SVP of U.S. business operations, a job she’s held since early 2016. Before that, she spent 16-plus years climbing the Amgen ladder, taking on projects that included launching anti-inflammatory blockbuster Enbrel. . . ."
I find an “extensive search” hard to believe. Her reputation precedes her. A game of musical chairs more like at the SVP+ level within sectors.
